Tislelizumab plus AG regimen for long-term CR in 2 patients with metastatic BRCA-mutation pancreatic cancer: A case report.
[RATIONALE] An increased risk of pancreatic cancer (PC) is associated with breast cancer susceptibility gene (BRCA) mutations.
APA
Gao F, Xu X, et al. (2024). Tislelizumab plus AG regimen for long-term CR in 2 patients with metastatic BRCA-mutation pancreatic cancer: A case report.. Medicine, 103(52), e40997. https://doi.org/10.1097/MD.0000000000040997
MLA
Gao F, et al.. "Tislelizumab plus AG regimen for long-term CR in 2 patients with metastatic BRCA-mutation pancreatic cancer: A case report.." Medicine, vol. 103, no. 52, 2024, pp. e40997.
PMID
39969335
Abstract
[RATIONALE] An increased risk of pancreatic cancer (PC) is associated with breast cancer susceptibility gene (BRCA) mutations. Given limited therapies, there remains an urgent need to explore novel treatment strategies.
[PATIENT CONCERNS] We report 2 metastatic PC patients with BRCA mutations who initially did not respond to standard therapies.
[DIAGNOSES] Case 1 was diagnosed with metastatic PC harboring a BRCA1 mutation, and case 2 was diagnosed with metastatic PC harboring a BRCA2 mutation.
[INTERVENTIONS] Both patients received a modified AG regimen (albumin-bound paclitaxel plus oxaliplatin) combined with tislelizumab, followed by maintenance therapy with olaparib plus tislelizumab after 6 cycles.
[OUTCOMES] Both patients achieved complete response, with complete response lasting for 19 months in case 1 and 18 months in case 2.
[LESSONS] The combination of triple therapy followed by maintenance therapy shows promise as a potential treatment option for PC patients with BRCA mutations. Further clinical investigation is needed to confirm its efficacy and safety.
[PATIENT CONCERNS] We report 2 metastatic PC patients with BRCA mutations who initially did not respond to standard therapies.
[DIAGNOSES] Case 1 was diagnosed with metastatic PC harboring a BRCA1 mutation, and case 2 was diagnosed with metastatic PC harboring a BRCA2 mutation.
[INTERVENTIONS] Both patients received a modified AG regimen (albumin-bound paclitaxel plus oxaliplatin) combined with tislelizumab, followed by maintenance therapy with olaparib plus tislelizumab after 6 cycles.
[OUTCOMES] Both patients achieved complete response, with complete response lasting for 19 months in case 1 and 18 months in case 2.
[LESSONS] The combination of triple therapy followed by maintenance therapy shows promise as a potential treatment option for PC patients with BRCA mutations. Further clinical investigation is needed to confirm its efficacy and safety.
MeSH Terms
Humans; Pancreatic Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Middle Aged; Female; Antibodies, Monoclonal, Humanized; Mutation; Paclitaxel; Albumins; Oxaliplatin; BRCA2 Protein; Male; Aged; Phthalazines; Piperazines
같은 제1저자의 인용 많은 논문 (5)
- Regulation of Cell Function and Myeloid-Derived Suppressor Cell Chemotaxis by hsa_circ_0006466-miR-1286-PDGFRA/B Axis in Triple Negative Breast Cancer.
- Xeroderma pigmentosum with multiple skin carcinoma and a homogenous mutation: A case report from China and literature review.
- Tumor-Selective Autophagy Blockade of Renal-Clearable BiS Nanoflowers for Precise Photothermal Therapy.
- The Temporal Trends and Attributed Risk Burden of Kidney Cancer, Bladder Cancer, and Prostate Cancer in China From 1990 to 2021.
- Expression characteristics and biological functions of CGB5 gene in gastric cancer.